Study | Country | Patients | Controls | Patients | Controls | OR | SE | Lower Limit | Upper Limit | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
[Refs.] | C | T (%) | C | T (%) | ||||||||
[ | Egypt | 139 | 90 | 133 | 125 (48.45) | 126 | 54 (30.00) | 2.19 | 0.20 | 1.47 | 3.28 | 0.000 A |
[ | Egypt | 107 | 107 | 163 | 51 (23.83) | 156 | 58 (27.10) | 0.84 | 0.22 | 0.54 | 1.30 | 0.438 |
[ | Algeria | 74 | 84 | 95 | 55 (36.67) | 110 | 58 (35.52) | 1.10 | 0.23 | 0.69 | 1.74 | 0.690 |
[ | Morocco | 344 | 690 | 523 | 165 (23.98) | 988 | 392 (28.41) | 0.80 | 0.11 | 0.64 | 0.98 | 0.033 |
[ | China | 182 | 53 | 140 | 224 (61.54) | 58 | 48 (45.28) | 1.93 | 0.22 | 1.25 | 2.99 | 0.003 A |
[ | China | 355 | 252 | 420 | 290 (40.85) | 351 | 153 (30.36) | 1.58 | 0.12 | 1.24 | 2.02 | 0.000 A |
[ | China | 75 | 72 | 92 | 58 (38.67) | 108 | 36 (25.00) | 1.89 | 0.26 | 1.15 | 3.12 | 0.013 A |
[ | China | 82 | 133 | 64 | 100 (60.98) | 133 | 133 (50.00) | 1.56 | 0.20 | 1.05 | 2.32 | 0.027 A |
[ | China | 131 | 293 | 125 | 139 (52.65) | 338 | 248 (42.32) | 1.52 | 0.15 | 1.13 | 2.03 | 0.005 A |
[ | China | 290 | 90 | 216 | 364 (62.76) | 95 | 85 (47.22) | 1.88 | 0.17 | 1.34 | 2.64 | 0.000 A |
[ | China | 271 | 180 | 262 | 280 (51.66) | 149 | 211 (58.61) | 0.75 | 0.14 | 0.58 | 0.99 | 0.040 A |
[ | India | 151 | 200 | 250 | 52 (17.22) | 363 | 37 (9.25) | 2.04 | 0.23 | 1.30 | 3.20 | 0.002 A |
[ | India | 522 | 315 | 872 | 172 (16.48) | 560 | 70 (11.11) | 1.58 | 0.15 | 1.17 | 2.12 | 0.003 A |
[ | India | 12 | 20 | 13 | 11 (45.83) | 37 | 3 (7.50) | 10.44 | 0.73 | 2.51 | 43.37 | 0.001 A |
[ | India | 637 | 364 | 1048 | 226 (17.74) | 627 | 99 (13.64) | 1.37 | 0.13 | 1.06 | 1.76 | 0.017 A |
[ | India | 206 | 230 | 358 | 54 (13.11) | 418 | 42 (9.13) | 1.50 | 0.22 | 0.98 | 2.30 | 0.062 |
[ | India | 179 | 200 | 239 | 119 (33.24) | 240 | 160 (40.00) | 0.75 | 0.15 | 0.55 | 1.01 | 0.054 |
[ | India | 100 | 100 | 186 | 14 (7.00) | 181 | 19 (9.50) | 0.72 | 0.37 | 0.35 | 1.47 | 0.365 |
[ | Iran | 164 | 328 | 196 | 132 (40.24) | 436 | 220 (33.54) | 1.33 | 0.14 | 1.01 | 1.67 | 0.039 A |
[ | Iran | 118 | 132 | 161 | 75 (31.78) | 206 | 58 (21.97) | 1.65 | 0.20 | 1.11 | 2.47 | 0.014 A |
[ | Iran | 242 | 255 | 327 | 157 (32.44) | 386 | 124 (24.31) | 1.49 | 0.14 | 1.13 | 1.97 | 0.005 A |
[ | Iran | 266 | 77 | 402 | 130 (24.44) | 74 | 80 (51.95) | 0.30 | 0.19 | 0.21 | 0.43 | 0.100 |
[ | Iran | 300 | 303 | 430 | 170 (28.33) | 426 | 180 (29.70) | 0.94 | 0.13 | 0.73 | 1.20 | 0.600 |
[ | Korea | 371 | 396 | 410 | 332 (44.73) | 490 | 302 (38.13) | 1.31 | 0.10 | 1.07 | 1.61 | 0.009 A |
[ | Korea | 360 | 325 | 411 | 309 (42.92) | 402 | 248 (38.15) | 1.22 | 0.11 | 0.98 | 1.51 | 0.073 |
[ | Korea | 85 | 246 | 104 | 66 (38.82) | 280 | 212 (43.09 | 0.84 | 0.18 | 0.59 | 1.20 | 0.332 |
[ | Brazil | 156 | 233 | 222 | 90 (28.85) | 387 | 79 (16.95) | 1.99 | 0.18 | 1.41 | 2.80 | 0.000 A |
[ | Brazil | 133 | 173 | 183 | 83 (68.80) | 299 | 47 (13.85) | 2.89 | 0.21 | 1.93 | 4.31 | 0.000 A |
[ | Slovenia | 100 | 111 | 109 | 91 (45.50) | 144 | 78 (35.14) | 1.54 | 0.20 | 1.04 | 2.28 | 0.030 A |
[ | Italy | 59 | 46 | 54 | 64 (54.24) | 57 | 35 (38.04) | 1.93 | 0.28 | 1.11 | 3.36 | 0.020 A |
[ | Italy | 93 | 105 | 111 | 75 (40.32) | 119 | 91 (43.33) | 0.88 | 0.20 | 0.59 | 1.32 | 0.545 |
[ | Turkey | 100 | 50 | 132 | 68 (34.00) | 80 | 20 (20.00) | 2.06 | 0.29 | 1.16 | 3.65 | 0.013 A |
[ | Germany | 255 | 200 | 321 | 189 (37.09) | 273 | 127 (31.75) | 1.27 | 0.14 | 0.96 | 1.67 | 0.095 |
[ | The Netherlands | 77 | 113 | 112 | 42 (27.27) | 148 | 78 (34.51) | 0.71 | 0.23 | 0.45 | 1.11 | 0.137 |
[ | Serbia | 52 | 56 | 68 | 36 (34.62) | 72 | 40 (35.71) | 0.95 | 0.29 | 0.54 | 1.67 | 0.866 |
[ | Poland | 284 | 352 | 399 | 169 (29.75) | 482 | 222 (31.53) | 0.92 | 0.12 | 0.72 | 1.17 | 0.494 |
[ | Jordan | 150 | 150 | 197 | 103 (34.33) | 215 | 85 (28.33) | 1.32 | 0.18 | 0.97 | 1.87 | 0.114 |
[ | Sweden | 149 | 182 | 209 | 89 (29.87) | 261 | 103 (28.30) | 1.08 | 0.17 | 0.77 | 1.51 | 0.658 |
[ | France | 250 | 114 | 337 | 163 (32.00) | 150 | 78 (34.21) | 0.93 | 0.17 | 0.67 | 1.30 | 0.668 |
[ | Russia | 180 | 301 | 250 | 110 (30.56) | 421 | 181 (30.07) | 1.02 | 0.14 | 0.77 | 1.36 | 0.873 |
[ | Canada | 39 | 19 | 58 | 20 (51.22) | 21 | 17 (44.74) | 0.43 | 0.42 | 0.19 | 0.96 | 0.041 A |
Patient Group | Allele | Infertile Men | Fertile Men | OR (95% CI) | AOR (95% CI) | ||
---|---|---|---|---|---|---|---|
Azoospermic | C | 90 (78.95) | 404 (92.66) | 1 | 0.000 | 1 | 0.017 A |
Oligospermic | C | 95 (71.97) | 404 (92.66) | 1 | 0.000 | 1 | 0.000 A |
Asthenozoospermic | C | 64 (72.73) | 404 (92.66) | 1 | 0.000 | 1 | 0.001 A |
Teratozoospermic | C | 41 (70.69) | 404 (92.66) | 1 | 0.000 | 1 | 0.000 A |
OAT | C | 29 (72.50) | 404 (92.66) | 1 | 0.021 | 1 | 0.008 A |
Infertile normospermic | C | 387 (87.56) | 404 (92.66) | 1 | 0.581 | 1 | 0.018 A |
Total infertile subjects | C | 706 (80.78) | 404 (92.66) | 1 | 0.012 | 1 | 0.016 A |
Study | Country | Patients | Controls | Patients | Controls | OR | SE | Lower Limit | Upper Limit | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
[Refs.] | CC | CT + TT (%) | CC | CT + TT (%) | ||||||||
[ | Egypt | 139 | 90 | 109 | 133 (54.96) | 144 | 111 (43.53) | 1.58 | 0.18 | 1.11 | 2.26 | 0.011 A |
[ | Egypt | 107 | 107 | 55 | 84 (60.43) | 41 | 49 (54.44) | 1.28 | 0.27 | 0.75 | 2.18 | 0.370 |
[ | Algeria | 74 | 84 | 31 | 43 (58.11) | 36 | 48 (57.14) | 1.04 | 0.32 | 0.55 | 1.96 | 0.902 |
[ | Morocco | 344 | 690 | 199 | 145 (42.15) | 351 | 339 (49.13) | 0.75 | 0.13 | 0.58 | 0.98 | 0.034 A |
[ | China | 182 | 53 | 27 | 155 (85.16) | 15 | 38 (71.70) | 2.27 | 0.37 | 1.10 | 4.67 | 0.027 A |
[ | China | 355 | 252 | 130 | 225 (63.38) | 128 | 124 (49.21) | 1.79 | 0.17 | 1.29 | 2.48 | 0.001 A |
[ | China | 75 | 72 | 27 | 48 (64.00) | 40 | 32 (44.44) | 2.22 | 0.34 | 1.15 | 4.31 | 0.018 A |
[ | China | 82 | 133 | 14 | 68 (82.93) | 36 | 97 (72.93) | 1.80 | 0.35 | 0.90 | 3.60 | 0.095 |
[ | China | 131 | 293 | 35 | 97 (73.48) | 98 | 293 (74.94) | 0.93 | 0.23 | 0.59 | 1.45 | 0.741 |
[ | China | 290 | 90 | 39 | 251 (86.55) | 24 | 66 (73.33) | 2.34 | 0.29 | 1.32 | 4.16 | 0.004 A |
[ | China | 271 | 180 | 75 | 196 (72.32) | 32 | 148 (82.22) | 0.57 | 0.24 | 0.35 | 0.90 | 0.016 A |
[ | India | 151 | 200 | 105 | 46 (30.46) | 163 | 37 (18.50) | 1.93 | 0.25 | 1.17 | 3.17 | 0.010 A |
[ | India | 522 | 315 | 378 | 144 (27.59) | 251 | 64 (20.32) | 1.49 | 0.17 | 1.07 | 2.09 | 0.019 A |
[ | India | 12 | 20 | 4 | 8 (66.67) | 18 | 2 (10.00) | 18.00 | 0.96 | 2.72 | 19.23 | 0.003 A |
[ | India | 637 | 364 | 447 | 190 (29.83) | 275 | 89 (24.45) | 1.31 | 0.15 | 0.98 | 1.76 | 0.068 |
[ | India | 206 | 230 | 158 | 48 (23.30) | 188 | 42 (18.26) | 1.36 | 0.24 | 0.85 | 2.16 | 0.195 |
[ | India | 179 | 200 | 81 | 98 (54.75) | 70 | 130 (65.00) | 0.65 | 0.21 | 0.43 | 0.99 | 0.042 A |
[ | India | 100 | 100 | 86 | 14 (14.00) | 81 | 19 (19.00) | 0.69 | 0.38 | 0.33 | 1.48 | 0.342 |
[ | Iran | 164 | 328 | 58 | 106 (64.63) | 144 | 184 (56.10) | 1.43 | 0.20 | 0.97 | 2.11 | 0.070 |
[ | Iran | 118 | 132 | 51 | 67 (56.78) | 77 | 55 (41.67) | 1.84 | 0.26 | 1.11 | 3.04 | 0.017 A |
[ | Iran | 242 | 255 | 109 | 133 (54.96) | 144 | 111 (43.53) | 1.58 | 0.18 | 1.11 | 2.26 | 0.011 A |
[ | Iran | 266 | 77 | 153 | 113 (42.48) | 33 | 44 (57.14) | 0.55 | 0.26 | 0.33 | 0.92 | 0.024 A |
[ | Iran | 300 | 303 | 161 | 139 (46.33) | 151 | 152 (50.17) | 0.86 | 0.16 | 0.62 | 1.18 | 0.347 |
[ | Korea | 371 | 396 | 103 | 268 (72.24) | 145 | 251 (63.38) | 1.50 | 0.16 | 1.11 | 2.04 | 0.009 A |
[ | Korea | 360 | 325 | 115 | 245 (68.06) | 118 | 207 (63.69) | 1.21 | 0.16 | 0.88 | 1.67 | 0.229 |
[ | Korea | 85 | 246 | 30 | 55 (64.71) | 87 | 159 (64.63) | 1.00 | 0.26 | 0.60 | 1.68 | 0.990 |
[ | Brazil | 156 | 233 | 81 | 75 (48.08) | 167 | 66 (28.33) | 2.34 | 0.22 | 1.53 | 3.58 | 0.000 A |
[ | Brazil | 133 | 173 | 66 | 67 (50.38) | 136 | 37 (21.39) | 3.73 | 0.25 | 2.27 | 6.14 | 0.000 A |
[ | Slovenia | 100 | 111 | 29 | 71 (71.00) | 47 | 64 (57.66) | 1.80 | 0.29 | 1.01 | 3.19 | 0.045 A |
[ | Italy | 59 | 46 | 11 | 48 (81.36) | 18 | 28 (60.87) | 2.81 | 0.45 | 1.16 | 6.78 | 0.022 A |
[ | Italy | 93 | 105 | 37 | 56 (60.22) | 43 | 62 (59.05) | 1.05 | 0.29 | 0.59 | 1.85 | 0.867 |
[ | Turkey | 100 | 50 | 44 | 56 (56.00) | 30 | 20 (40.00) | 1.91 | 0.35 | 0.96 | 3.81 | 0.066 |
[ | Germany | 255 | 200 | 114 | 141 (55.29) | 92 | 108 (54.00) | 1.05 | 0.19 | 0.73 | 1.53 | 0.783 |
[ | The Netherlands | 77 | 113 | 42 | 35 (45.45) | 50 | 63 (55.75) | 0.66 | 0.30 | 0.37 | 1.18 | 0.164 |
[ | Serbia | 52 | 56 | 22 | 30 (57.69) | 23 | 33 (58.93) | 0.95 | 0.39 | 0.44 | 2.04 | 0.896 |
[ | Poland | 284 | 352 | 143 | 256 (64.16) | 166 | 316 (65.56) | 0.94 | 0.14 | 0.71 | 1.24 | 0.665 |
[ | Jordan | 150 | 150 | 67 | 83 (55.33) | 74 | 76 (50.67) | 1.21 | 0.23 | 0.77 | 1.90 | 0.418 |
[ | Sweden | 149 | 182 | 73 | 76 (51.01) | 94 | 88 (48.35) | 1.11 | 0.22 | 0.72 | 1.72 | 0.631 |
[ | France | 250 | 114 | 118 | 132 (52.80) | 49 | 65 (57.02) | 0.84 | 0.23 | 0.54 | 1.32 | 0.454 |
[ | Russia | 180 | 301 | 89 | 91 (50.56) | 153 | 148 (49.17) | 1.06 | 0.19 | 0.73 | 1.53 | 0.769 |
[ | Canada | 39 | 19 | 22 | 17 (43.59) | 8 | 11 (57.89) | 0.56 | 0.57 | 0.19 | 1.70 | 0.308 |
Patient Group | Genotype | Infertile Men | Fertile Men | OR (95% CI) | AOR (95% CI) | ||
---|---|---|---|---|---|---|---|
Azoospermic | CC | 36 (63.16) | 187 (85.78) | 1 | 1 | A A A | |
Oligospermic | CC | 34 (51.52) | 187 (85.78) | 1 | 1 | A A A | |
Asthenozoospermic | CC | 22 (50.00) | 187 (85.78) | 1 | 1 | A A A | |
Teratozoospermic | CC | 15 (51.72) | 187 (85.78) | 1 | 1 | A A A | |
OAT | CC | 10 (50.00) | 187 (85.78) | 1 | 1 | A A | |
Infertile normospermic | CC | 168 (76.02) | 187 (85.78) | 1 | 1 | A A | |
Total infertile subjects | CC | 285 (65.22) | 187 (85.78) | 1 | 1 | A A A |